ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2035

Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease

Dizon Brian1, Matthew Basiaga2, Sara Stern3, Akaluck Thatayatikom4, seunghee cha5, Scott Lieberman6, Hemalatha Srinivasalu7 and on behalf of CARRA and the childhood Sjogren's workgroup8, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Mayo Clinic, Inver Grove Heights, MN, 3University of Utah, Salt Lake City, UT, 4AdventHealth, Orlando, FL, 5University of Florida, Gainesville, FL, 6University of Iowa, Iowa City, IA, 7Children's National Hospital, Washington, DC, 8Childhood Arthritis and Rheumatology Research Alliance, Bethesda, MD

Meeting: ACR Convergence 2022

Keywords: Pediatric rheumatology, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Sjögren’s disease is a rare condition in children. Diagnosis is often delayed because of the lack of pediatric-specific guidelines for childhood Sjögren’s disease (cSjD). In a retrospective cohort generated by the Childhood Sjögren’s Disease Workgroup, minor salivary gland (MSG) biopsy was performed as part of the evaluation for cSjD in 56% of the patients (Basiaga et al), suggesting the presence of factors which influence how MSG biopsy is utilized in the evaluation of cSjD.

Methods: Using the retrospective international cohort of 300 children diagnosed with cSjD, we compared demographics, clinical manifestations, disease features, and diagnostic evaluation of cSjD patients who underwent MSG biopsy as part of their evaluation of cSjD to those who did not.

Results: We found that younger age (less than 9 years old, p=0.0003, OR 2.9), male biologic sex (p=0.005, OR 2.4), parotitis (p< 0.0001, OR 2.8), and dry mouth (p=0.01, OR 1.8) were associated with a higher likelihood of MSG biopsy (Table 1). Hypergammaglobulinemia (p=0.0001, OR 0.36) and serologies positive for SSA (p < 0.0001, OR 0.14), SSB (p< 0.0001, OR 0.30), RF (p=0.04, OR 0.59), and ANA (p=0.002, OR 0.33), all of which strongly support cSjD, were associated with a lower likelihood of MSG biopsy (Table 2). The presence of cytopenia and proteinuria were significantly increased in patients diagnosed with cSjD who did not undergo MSG biopsy (Table 2). To examine how variation in provider practice influenced the use of MSG biopsy, we stratified patients according to contributing provider, which interestingly revealed a bimodal distribution of usage of MSG biopsy, supporting a wide variation in the use of MSG biopsy for the evaluation of cSjD. In contrast to providers who routinely evaluated with MSG biopsy, those who did not routinely evaluate with MSG biopsy also had reduced use of other diagnostic evaluations, including Schirmer test (p=0.001), ocular staining score (p< 0.0001), unstimulated salivary flow (p< 0.0001), and salivary gland ultrasound (p< 0.0001), further supporting the wide practice variation in the evaluation of cSjD.

Conclusion: Taken together, these findings suggest that a standardized evaluation of cSjD is needed to improve diagnosis and to better understand the epidemiology and natural history of this rare clinical entity, and ultimately provide the foundation for clinical trials for the treatment of cSjD.

References:
Basiaga, ML et al. Childhood Sjögren’s Syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria. Rheumatology, Volume 60, Issue 7, July 2021, Pages 3144–3155.

Supporting image 1

Table 1. Comparison of demographics and clinical manifestations between cSjD patients evaluated without MSG biopsy (-biopsy) versus those who were evaluated with MSG biopsy (+biopsy). Statistical significance was determined by Chi square analysis or Fisher’s exact test with smaller sample sizes, and p value of <0.05 was considered statistically significant.

Supporting image 2

Table 2. Comparison of diagnostic testing and and serologies between cSjD patients evaluated without MSG biopsy (-biopsy) versus those who were evaluated with MSG biopsy (+biopsy). Statistical significance was determined by Chi square analysis or Fisher’s exact test with smaller sample sizes, and p value of <0.05 was considered statistically significant.


Disclosures: D. Brian, None; M. Basiaga, None; S. Stern, None; A. Thatayatikom, None; s. cha, None; S. Lieberman, None; H. Srinivasalu, None; o. CARRA and the childhood Sjogren's workgroup, None.

To cite this abstract in AMA style:

Brian D, Basiaga M, Stern S, Thatayatikom A, cha s, Lieberman S, Srinivasalu H, CARRA and the childhood Sjogren's workgroup o. Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/elucidating-the-factors-that-influence-the-use-of-minor-salivary-gland-biopsy-for-the-evaluation-of-childhood-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elucidating-the-factors-that-influence-the-use-of-minor-salivary-gland-biopsy-for-the-evaluation-of-childhood-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology